Enanta Pharmaceuticals, Inc.
Moat Score — Enanta Pharmaceuticals, Inc.
Total Moat Score
6 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Patents on glecaprevir and pipeline compounds plus a validated small-molecule chemistry discovery platform have real value, but most pipeline IP is unproven in late-stage trials and not yet commercialized. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | As a small clinical-stage biotech, Enanta has no manufacturing or operating cost advantage versus larger, better-capitalized pharmaceutical competitors. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 0 / 5 | Enanta sets no prices itself; its only commercial product (MAVYRET/MAVIRET) is priced and sold entirely by AbbVie, and unpartnered pipeline assets generate no revenue at all yet. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | No network effect exists in small-molecule drug discovery and development. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | Once a drug is approved and prescribed, there is some physician/patient switching inertia, but Enanta's only marketed asset is controlled by AbbVie and its pipeline assets are pre-commercial with no switching costs yet established. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | Biotech R&D does not require large fixed infrastructure the way manufacturing does, so there is little efficient-scale barrier; Enanta's small size is actually a disadvantage against larger virology/immunology competitors with greater resources. |